ATORVASTATIN CALCIUM - Generic Drug Details

What are the generic sources for atorvastatin calcium and what is the scope of freedom to operate?

Atorvastatin calcium is the generic ingredient in five branded drugs marketed by Cmp Dev Llc, Accord Hlthcare, Alkem Labs Ltd, Apotex, Apotex Inc, Aurobindo Pharma Ltd, Biocon Pharma, Cadila Pharms Ltd, Chartwell Rx, Dr Reddys, Dr Reddys Labs Ltd, Graviti Pharms, Hetero Labs Ltd V, Invagen Pharms, Lannett Co Inc, Laurus, Lepu Pharm, Lupin Ltd, Macleods Pharms Ltd, Mankind Pharma, Micro Labs Ltd India, MSN, Mylan Pharms Inc, Perrigo R And D, Sciegen Pharms, Shandong Xinhua, Strides Pharma, Sun Pharm Inds Ltd, Teva Pharms, Teva Pharms Inc, Teva Pharms Usa, Umedica, Zydus Pharms, Upjohn, Organon, and Pharmobedient, and is included in thirty-seven NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Atorvastatin calcium has two patent family members in two countries.

There are fifty-five drug master file entries for atorvastatin calcium. Fifty-nine suppliers are listed for this compound.

Summary for ATORVASTATIN CALCIUM

International Patents:	2
US Patents:	5
Tradenames:	5
Applicants:	36
NDAs:	37
Drug Master File Entries:	55
Finished Product Suppliers / Packagers:	59
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	72
Patent Applications:	5,979
Drug Sales Revenues:	Drug sales revenues for ATORVASTATIN CALCIUM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ATORVASTATIN CALCIUM
What excipients (inactive ingredients) are in ATORVASTATIN CALCIUM?	ATORVASTATIN CALCIUM excipients list
DailyMed Link:	ATORVASTATIN CALCIUM at DailyMed

See drug sales revenues for ATORVASTATIN CALCIUM

Recent Clinical Trials for ATORVASTATIN CALCIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pharma Medica Research, Inc.	Phase 1
NewAmsterdam Pharma	Phase 1
University of California, San Francisco	Phase 2

See all ATORVASTATIN CALCIUM clinical trials

Pharmacology for ATORVASTATIN CALCIUM

Drug Class	HMG-CoA Reductase Inhibitor
Mechanism of Action	Hydroxymethylglutaryl-CoA Reductase Inhibitors

Medical Subject Heading (MeSH) Categories for ATORVASTATIN CALCIUM

Anticholesteremic Agents

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for ATORVASTATIN CALCIUM

C10AA	HMG CoA reductase inhibitors
C10A	LIPID MODIFYING AGENTS, PLAIN
C10	LIPID MODIFYING AGENTS
C	Cardiovascular system

US Patents and Regulatory Information for ATORVASTATIN CALCIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys Labs Ltd	ATORVASTATIN CALCIUM	atorvastatin calcium	TABLET;ORAL	091650-002	Jul 17, 2012	AB	RX	No	No
Laurus	ATORVASTATIN CALCIUM	atorvastatin calcium	TABLET;ORAL	214513-003	Jan 22, 2024	AB	RX	No	No
Alkem Labs Ltd	ATORVASTATIN CALCIUM	atorvastatin calcium	TABLET;ORAL	209288-002	Dec 21, 2018	AB	RX	No	No
Shandong Xinhua	ATORVASTATIN CALCIUM	atorvastatin calcium	TABLET;ORAL	211886-001	Jan 25, 2024	AB	RX	No	No

Expired US Patents for ATORVASTATIN CALCIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-003	Dec 17, 1996	5,385,929
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-001	Dec 17, 1996	5,385,929
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-004	Apr 7, 2000	5,969,166
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-002	Dec 17, 1996	5,385,929

International Patents for ATORVASTATIN CALCIUM

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3468606	NOUVELLE COMPOSITION PHARMACEUTIQUE DE COMPOSÉ HYPOLIPIDÉMIANT (A NOVEL PHARMACEUTICAL COMPOSITION OF A LIPID LOWERING COMPOUND)
European Patent Office	3468606
World Intellectual Property Organization (WIPO)	2017212409

Supplementary Protection Certificates for ATORVASTATIN CALCIUM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0720599	300689	Netherlands		PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912
1003503	SZ 30/2006	Austria		PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SÄUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN
0247633	C970034	Netherlands		PRODUCT NAME: ATORVASTATINUM,DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF VAN HET INWENDIGE DELTA-LACTON, IN HET BIJZONDER ATORVASTATINUM CALCICUM TRIHYDRICUM; NAT. REGISTRATION NO/DATE: RVG 21081 - RVG 21083 19970421; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
1003503	30/2006	Austria		PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SAEUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN; NAT. REGISTRATION NO/DATE: 1-26271, 1-26273 20060330; FIRST REGISTRATION: FR 369300.9;369301.5; 369302.1;369303.8;369304.4;369305.0; 20050707

Market Dynamics and Financial Trajectory for Atorvastatin Calcium

Last updated: April 21, 2026

What Is the Current Market Size for Atorvastatin Calcium?

The global market for atorvastatin calcium was valued at approximately $12 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 3.5% from 2023 to 2030, reaching an estimated $16 billion by 2030.

Key Drivers:

• Increasing prevalence of cardiovascular diseases (CVD).
• Rising awareness of hyperlipidemia treatment.
• Patent expirations leading to generic proliferation.

Geographic Breakdown:

• North America: 45% of revenue, driven by high CVD prevalence and established healthcare infrastructure.
• Europe: 25%, with significant growth in Spain, Germany, and the UK.
• Asia-Pacific: 20%, driven by emerging markets like India and China.
• Rest of World (RoW): 10%, with increasing acceptance of generic drugs.

How Does Patent Status Influence Market Dynamics?

The original patent for atorvastatin calcium expired in 2011, resulting in a surge of generic versions. Major pharmaceutical companies, such as Teva and Mylan, introduced generic atorvastatin shortly after patent expiry, significantly reducing brand-name sales.

Impact:

• Onset of generic competition led to a price erosion of up to 80%, decreasing profit margins.
• Controlled-release formulations and fixed-dose combinations retained higher prices.
• Brand-name market share shrank to less than 20% globally by 2022.

What Are the Key Competitive Products and Approvals?

Generic atorvastatin remains the dominant product. However, several modifications and combination therapies are entering the market:

• Fixed-dose combinations with amlodipine (for hypertension and hyperlipidemia).
• Higher-dosage formulations for severe cases.
• Injectable forms under investigation for specific indications.

Regulatory authorities, like the FDA and EMA, have mostly approved these variants, with some requiring post-marketing safety data.

How Do Pricing Trends Affect Revenue and Profitability?

Prices for generic atorvastatin have declined by approximately 78% since 2012. The average wholesale price (AWP) of a 30-day supply in the U.S. dropped from around $150 in 2011 to approximately $35 in 2022.

Revenue Implications:

• Leading manufacturers have offset margin erosion through increased volume sales.
• Margins for brand-name formulations are under continued pressure.
• Cost-cutting and operational efficiency are prioritized in manufacturing.

What Are the Future R&D and Market Expansion Trends?

Research on novel lipid-lowering agents and combination therapies is ongoing. Focus areas include:

• Incorporating PCSK9 inhibitors with atorvastatin to enhance efficacy.
• Developing long-acting formulations for compliance.
• Exploration of biosimilars and biobetters.

Market entrants are also targeting emerging economies with cost-effective formulations.

What Is the Anticipated Financial Trajectory?

Projected sales for atorvastatin calcium are expected to plateau at around $15-16 billion by 2030, reflecting mature market saturation in developed regions.

Revenue Growth Breakdown:

Year	Projected Market Value	Key Factors
2023	$12.4 billion	Generics expansion, patent expiry impact diminishes
2025	$13.0 billion	Introduction of combination therapies
2030	$16.0 billion	Emerging markets expansion, reformulation launches

Profitability margins are stabilized through diversified portfolios and extension into adjunct therapies.

Key Takeaways

• The atorvastatin calcium market experienced significant growth driven by CVD prevalence, with a shift toward generics after patent expiry.
• Price erosion has been substantial, yet volume and new formulations sustain revenue.
• Competition focuses on combination therapies and formulations for specialized indications.
• The market is close to saturation in developed markets, with growth driven by emerging economies.
• Future R&D emphasizes combination treatments, biosimilars, and long-acting formulations to sustain revenue.

FAQs

1. How has patent expiration affected atorvastatin calcium sales?
Patent expiration in 2011 led to a surge in generic versions, reducing brand-name sales and sharply decreasing prices, but overall volume sales increased.

2. Are there any upcoming formulations or indications for atorvastatin calcium?
Yes, fixed-dose combination pills and injectable formulations are under development; some are seeking approval for use in specific patient populations.

3. How significant is the generic market share in 2023?
Generic atorvastatin accounts for approximately 80% of global sales, with brand-name sales confined mainly to specific regions or formulations.

4. What regional markets show the highest growth potential?
Emerging economies like India and China present the highest growth potential due to rising CVD rates and lower drug prices.

5. What are the main competitive threats to atorvastatin calcium market longevity?
New lipid-lowering agents, including PCSK9 inhibitors, and alternative therapies pose long-term threats to atorvastatin's market dominance.

---

References

1. MarketsandMarkets. (2023). Global lipid regulation therapeutics market.
2. IQVIA. (2022). Pharmaceutical sales data.
3. U.S. Food and Drug Administration. (2023). Drug approvals and formulations.
4. GlobalData. (2023). Generic drugs market outlook.
5. IMS Health. (2022). Market analysis of cardiovascular drugs.